Longboard Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Longboard Pharmaceuticals

02/11/2023 21:21

* Longboard Pharmaceuticals Inc  LBPH.OQ  reported a
quarterly
adjusted loss of 55 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -68 cents.  The mean expectation of
six analysts for the quarter was for a loss of 70 cents per
share. Wall Street expected results to range from -76 cents
to -68 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Longboard Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 55 cents​.
    * The company reported a quarterly loss of $12.93 million.
    * Longboard Pharmaceuticals Inc shares had fallen by 3.6%
this
quarter and gained 64.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $16.00 
This summary was machine generated from LSEG data November 2 at
09:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.70          -0.55          Beat
 Jun. 30 2023      -0.60          -0.65          Missed
 Mar. 31 2023      -0.57          -0.56          Beat
 Dec. 31 2022      -0.69          -0.66          Beat